DSM has added Kremer Method™, an innovative proprietary technology to improve downstream processing of monoclonal antibodies for faster and more cost effective production of biopharmaceuticals. The Kremer Method reduces processing and preparation times, labor and materials requirements and cost of goods for a more sustainable manufacturing platform, according to DSM.

Karen King, president of DSM Biologics, commented, “DSM is continually innovating to advance the world of biopharmaceutical manufacturing to the next level. We are pleased to announce the introduction of the new DSP optimization technology, the Kremer Method. The combination of the Kremer Method with our other proprietary technologies significantly reduces the overall costs and processing times of biopharmaceuticals while maintaining high product quality.”

Rolf Douwenga, vice president of Global R&D for DSM Biologics, remarked, “The method uses in-line dilution to streamline the purification and polishing of MAbs into one single continuous step in a flow-through mode. This eliminates the need for storage and reduces the amount of material usage such as buffers and resins.”

After the capture step in conventional downstream processes, further purification and polishing of proteins are traditionally carried out as two separate batch unit operations. With the Kremer Method these steps are streamlined to work as a single unit operation. Using this method, the company reports, Host Cell Proteins (HCPs) were removed to a level below the limits of detection, complete aggregate removal was observed comparable to current state of the art processes, and recoveries of 90% were achieved. Several patent applications have already been filed.